Po-01-134 an international multicenter cohort study on beta-blocker free treatment strategies for catecholaminergic polymorphic ventricular tachycardia

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare potentially life-threatening genetic heart disease. Non-selective beta-blockers (BBs, namely nadolol and propranolol) are highly effective in reducing CPVT-triggered arrhythmic events. However, some patients suffer from unacceptable BB side effects and might require BB-free treatment strategies that include flecainide, left cardiac sympathetic denervation (LCSD), combination therapy, or potentially even intentional non-therapy (INT) as has been published for long QT syndrome.

Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Raquel A. Neves, Sahej Bains, Johan M. Bos, Christian van der Werf, Auke Bergeman, Puck Peltenburg, Shubhayan Sanatani, Heikki Swan, VINCENT PROBST, Prince J. Kannankeril, Jonathan R. Skinner, Ramon Brugada, Tomas Robyns, Martin M. Borggrefe, Wataru Shimi Source Type: research